LEGN

Legend Biotech Corp - ADR

Healthcare


Presented:10/13/2022
Price:$38.82
Cap:$5.93B
Current Price:$44.91
Cap:$8.23B

Presented

Date10/13/2022
Price$38.82
Market Cap$5.93B
Ent Value$4.95B
P/E RatioN/A
Book Value$2.87
Div Yield0%
Shares O/S152.83M
Ave Daily Vol768,599
Short IntN/A

Current

Price$44.91
Market Cap$8.23B
Legend Biotech Corp. is a holding company, which engages in the discovery and development of novel cell therapies for oncology and other indications. It operates through the North America and China geographical segments. The company was founded on May 27, 2015 and is headquartered in Somerset, NJ.

Publicly traded companies mentioned herein: Gilead Sciences Inc (GILD), Legend Biotech Corp (LEGN), Johnson & Johnson (JNJ)

Highlights

The presenter is long shares of Legend Biotech Corp (LEGN), a commercial-stage biotechnology company developing novel cell therapy treatments. He is excited about a multiple myeloma drug that will release data results later this year and feels that the drug is well-positioned to capture market share. Considering the potential for substantial revenue gains following approval, the presenter sees 100% long-term upside and thinks the current share price of ~$40 is an attractive entry point. 

  • Signing up and creating account with us unlocks this content for you. Contact us today for full access to DeMatteo Research and more.

  • Signing up and creating account with us unlocks this content for you. Contact us today for full access to DeMatteo Research and more.

Request access to DeMatteo Research for full access

Request Access

Already have an account?

Idea Discussion

Commentor 1 - 2 weeks ago

Signing up and creating account with us, unlocks this content for you. Contact us today for full access to DeMatteo Research and more.

Commentor 1 - 2 weeks ago

Signing up and creating account with us, unlocks this content for you. Contact us today for full access to DeMatteo Research and more.

Idea Discussions display submitted commentary from our investor community.

To read and participate in the discussion with the presenter and investor base, request access to DeMatteo

Request Access

Already have an account?

An error occurred loading this content. Try again later or contact us.